1. Home
  2. TTRX vs CSHRW Comparison

TTRX vs CSHRW Comparison

Compare TTRX & CSHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$9.52

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

CSHRW

CoinShares PLC Warrants

N/A

Current Price

$0.84

Market Cap

167.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TTRX
CSHRW
Founded
2015
N/A
Country
United States
Jersey
Employees
2
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Bankers/Brokers/Service
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
281.2M
167.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TTRX
CSHRW
Price
$9.52
$0.84
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$8.00
N/A
AVG Volume (30 Days)
95.2K
6.0K
Earning Date
05-31-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.57
$0.59
52 Week High
$11.69
$1.15

Technical Indicators

Market Signals
Indicator
TTRX
CSHRW
Relative Strength Index (RSI) 72.94 37.37
Support Level $4.40 $0.73
Resistance Level N/A $0.88
Average True Range (ATR) 1.02 0.16
MACD 0.23 -0.01
Stochastic Oscillator 64.47 44.74

Price Performance

Historical Comparison
TTRX
CSHRW

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: